Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 101 - 110 of 243
Alternative Name: HIFU
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: Vitality Medical Products
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Injectable Gestodene (GES) + Ethinyl Estradiol (EE)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Peking University
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Stanford University
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of California San Diego
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: KYDES Pharmaceuticals, FHI 360
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of Tennessee Health Sciences Center
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Gendarussa
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Airlangga University, Indopharma, FHI 360
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 61 - 70 of 70
User: Female
Hormonal: No
Developer: Rutgers University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Target
User: Male
Hormonal: No
Developer: Baylor College of Medicine, NICHD
Development Stage: Target Validation
Alternative Name: RISUG in the Fallopian Tube
User: Female
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Fallopian Tube
Developer: Indian Institute of Technology, Kharagpur
Development Stage: Prototype Development
Alternative Name: Tripterygium wilfordii derivatives, including triptolide
User: Male
Hormonal: No
Developer: WHO, University of California at Los Angeles
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: FHI 360, GE Healthcare
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Delivery Method: Vaginal, Other
Developer: University of Texas Health Science Center at San Antonio
Development Stage: Lead Optimization
Alternative Name: WEE1 HOMOLOG 2; WEE1B; WEE2 Kinase
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Lead Optimization
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization

Pages

Displaying 71 - 80 of 121
Alternative Name: Nestorone (NES) Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council
Development Stage: Phase II
Alternative Name: Nestorone + Testosterone Gel
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Development Stage: Phase II
Alternative Name: Nestorone (NES) Metered Dose Transdermal System® (MDTS®)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Acrux, Ltd., Fempharm Pty Ltd.
Development Stage: Phase I
Alternative Name: Nestorone (NES) + Estradiol (E2) Transdermal Gel
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Antares, Population Council
Development Stage: Phase II
Alternative Name: Biodegradable Norethindrone (NET) Pellets
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Anterion Therapeutics, FHI 360
Development Stage: Phase II
Alternative Name: Non-Invasive Laser Male Sterilization
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Vas Deferens
Developer: University of North Carolina at Charlotte
Development Stage: Pre-clinical
Alternative Name: Oil-based drospirenone (DSRP) microcrystal suspension
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Male
Hormonal: No
Delivery Method: Oral
Developer: South African Medical Research Council, University of Western Cape
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Alternative Name: ZK 98.299; ZK 98 299
User: Female
Hormonal: Yes
Developer: Schering AG
Development Stage: Pre-clinical

Pages

Displaying 31 - 40 of 52
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Alternative Name: Pregna PPIUD T Cu 380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited, IXu LLC
Development Stage: SRA/WHO PQ Approved

Pages

CSV